Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab versus lignocaine for inpatient treatment of status migrainosus
ACTRN12621001616864Phase 4Recruiting
- Sponsor
- Alfred Health
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of eptinezumab and lidocaine in migraine and status migrainosus (SM), sponsored by Alfred Health. Started Apr 2022; status: recruiting.
02
Drugs
eptinezumablidocaine
03
Conditions
migrainestatus migrainosus (SM)
Beyond the preview
Go deeper on ACTRN12621001616864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001616864.